Annexin A5 protein degradation inducer and application thereof
Through covalent binding of caffeic acid and Annexin A5 protein, it induces its degradation, solving the problems of high toxicity and limited effectiveness of existing IPF treatment drugs, and achieving safe and effective treatment of idiopathic pulmonary fibrosis.
Patent Information
- Application Number
- CN202410488297.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Although existing idiopathic pulmonary fibrosis (IPF) treatment drugs such as Pirfenidone and Nintedanib can delay disease progression, they are toxic and cost-effective, and have limited therapeutic effects on pulmonary fibrosis. There are no safe and effective drugs available. Alternative.
Caffeic acid is used as a targeted drug for the treatment of Annexin A5 related diseases by covalently binding to Cys316 of Annexin A5 protein, induces its hydrophobic exposure and degradation, thereby significantly inhibiting lung inflammation and fibrosis.
Caffeic acid significantly reduces pulmonary fibrosis and reduces inflammation levels at safe and effective doses. It is safer and more effective than the dose used for the positive drug pirfenidone.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004804852920000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to an Annexin A5 protein degradation inducer and application thereof. Background Art
[0002] In the field of pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF) is the most common and most serious form, which often occurs in middle-aged and elderly people. The two drugs on the market, Pirfenidone and Nintedanib, only play a role in delaying the progression of the disease, and are highly toxic and expensive. Therefore, more safe and effective drugs to improve or treat IPF are still needed.
[0003] Annexin A5 (ANXA5) is a widely distributed member of the calcium and phospholipid binding protein family, and is involved in a variety of physiological processes, such as inflammatory response, cell senescence and apoptosis. Evidence shows that ANXA5 protein was significantly increased in bronchoalveolar lavage fluid of people with interstitial lung disease and in the lung tissue of mice exposed to silica, suggesting that ANXA5 may play a role in the pathogenesis of pulmonary fibrosis-related diseases. Therefore, the development of small molecule compounds that can target and regulate ANXA5 protein, such as compounds that induce its degradation, can be used to treat pulmonary fibrosis. Summary of the invention
[0004] In order to solve one of the above-mentioned technical problems existing in the prior art, the present invention has found that the direct action target of caffeic acid in cells is Annexin A5 protein, and the covalent binding of caffeic acid to Annexin A5 protein will cause its degradation, and significantly inhibit the lung inflammation and fibrosis level of pulmonary fibrosis model mice. The present application has found that caffeic acid has excellent effects in reducing the inflammation level of the lungs and circulatory system. Therefore, by using Annexin A5 as the target of caffeic acid, drugs for precise intervention of aging-related diseases (such as idiopathic pulmonary fibrosis) can be prepared. Caffeic acid can be used as an Annexin A5 protein inhibitor or degrader.
[0005] In a first aspect, the present invention provides use of caffeic acid in preparing a drug for regulating or treating a disease associated with Annexin A5 protein or for degrading Annexin A5 protein, or use of caffeic acid in preparing a degradation inducer of Annexin A5 protein.
[0006] The present invention creatively discovered that caffeic acid can improve or treat diseases associated with Annexin A5 protein by inhibiting the activity of Annexin A5 protein or degrading Annexin A5 protein (caffeic acid directly binds to Cys316 on Annexin A5 protein, inducing its hydrophobic exposure and subsequent degradation).
[0007]
[0008] In some embodiments, caffeic acid inhibits inflammation by binding to Annexin A5 protein and causing its degradation.
[0009] In some embodiments, the Annexin A5 protein-related disease includes an aging-related disease.
[0010] In some embodiments, the Annexin A5 protein-related diseases include, but are not limited to, lung, brain, eye, heart, liver, kidney, blood vessel, bone, skin and / or joint diseases.
[0011] In some specific embodiments, the Annexin A5 protein-related diseases include lung diseases, such as pulmonary fibrosis, lung inflammation, etc.
[0012] In some embodiments, the Annexin A5 protein-related diseases include, but are not limited to, pulmonary fibrosis, pulmonary inflammation, chronic obstructive pulmonary disease, heart failure, myocardial hypertrophy, liver fibrosis, osteoarthritis, intervertebral disc herniation, osteoporosis, Alzheimer's disease, Parkinson's disease, arteriosclerosis, macular degeneration, diabetic nephropathy, diabetic macular edema, diabetic retinopathy, etc.
[0013] In some embodiments, the Annexin A5 protein-related disease includes pulmonary fibrosis. In some preferred embodiments, the Annexin A5 protein-related disease includes idiopathic pulmonary fibrosis.
[0014] In some embodiments, the Annexin A5 protein-related disease comprises lung inflammation.
[0015] In some embodiments, the drug or degradation inducing agent comprises caffeic acid.
[0016] In some embodiments, the drug or degradation inducer further comprises a pharmaceutically acceptable excipient.
[0017] In some embodiments, the excipients include but are not limited to: solvents, propellants, solubilizers, co-solvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, antioxidants, chelating agents, penetration enhancers, pH regulators, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents and filter aids, etc.
[0018] The dosage forms of the drug or degradation inducer of the present invention include but are not limited to: injection, tablet, capsule, aerosol, suppository, film, pellet, external ointment, controlled release preparation, sustained release preparation or nano preparation.
[0019] The drug or degradation inducer of the present invention comprises caffeic acid within a safe and effective amount and a pharmacologically acceptable auxiliary material or carrier, wherein "safe and effective amount" means that the amount of the active ingredient caffeic acid is sufficient to significantly improve the condition without causing serious side effects.
[0020] The present invention has no particular limitation on the administration method of the drug or degradation inducer. Representative administration methods include, but are not limited to, oral administration, parenteral administration (intravenous, intramuscular or subcutaneous), topical administration, and the like.
[0021] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active ingredient is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or solubilizers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid, etc.; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic, etc.; (c) humectants, such as glycerol; (d) disintegrators, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, etc.; (e) solubilizers, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol, glyceryl monostearate, etc.; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may also contain a buffer.
[0022] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active ingredient in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active ingredient can also be formed into microcapsules with one or more of the above-mentioned excipients.
[0023] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active ingredient, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
[0024] Besides these inert diluents, adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents may also be included.
[0025] In addition, the suspension may contain suspending agents, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances and the like.
[0026] Dosage forms for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0027] Dosage forms for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0028] In a second aspect, the present invention provides a method for regulating or treating an Annexin A5 protein-related disease, the method comprising administering a therapeutically effective amount of caffeic acid to a subject identified or diagnosed as having an Annexin A5 protein-related disease.
[0029] In some embodiments, the Annexin A5 protein-related disease includes an aging-related disease.
[0030] In some embodiments, caffeic acid regulates or treats aging-related diseases by targeting Annexin A5 protein.
[0031] In some embodiments, the Annexin A5 protein-related diseases include, but are not limited to, lung, brain, eye, heart, liver, kidney, blood vessel, bone, skin and / or joint diseases.
[0032] In some embodiments, the Annexin A5 protein-related disease includes at least one of pulmonary fibrosis, pulmonary inflammation, chronic obstructive pulmonary disease, heart failure, myocardial hypertrophy, liver fibrosis, osteoarthritis, intervertebral disc herniation, osteoporosis, Alzheimer's disease, Parkinson's disease, arteriosclerosis, macular degeneration, diabetic nephropathy, diabetic macular edema, and diabetic retinopathy.
[0033] In some embodiments, the Annexin A5 protein-related disease includes pulmonary fibrosis, such as idiopathic pulmonary fibrosis.
[0034] In some embodiments, the Annexin A5 protein-related disease comprises lung inflammation.
[0035] The method of the present invention can be used alone or in combination with other treatments or therapeutic drugs.
[0036] In a third aspect, the present invention provides a method for inhibiting Annexin A5 protein activity in a cell or a subject, the method comprising the step of contacting the cell or administering caffeic acid to the subject. In some embodiments, the method is for non-disease diagnosis purposes. In some embodiments, the method is for disease diagnosis purposes.
[0037] In some embodiments, the cell is a mammalian cell. In some embodiments, the subject is a mammal, preferably a human.
[0038] In a fourth aspect, the present invention provides a method for degrading Annexin A5 protein in a cell or a subject, the method comprising the step of contacting the cell or administering caffeic acid to the subject. In some embodiments, the method is for non-disease diagnosis purposes. In some embodiments, the method is for disease diagnosis purposes.
[0039] In some embodiments, the cell is a mammalian cell. In some embodiments, the subject is a mammal, preferably a human.
[0040] Compared with the prior art, the present invention has the following beneficial technical effects:
[0041] The present application has found that Annexin A5 protein is the covalent protein target of caffeic acid in cells, and further determined that caffeic acid directly binds to Cys316 on Annexin A5 protein, inducing its hydrophobic exposure and subsequent degradation. In addition, the present application also found that caffeic acid can reduce pulmonary fibrosis and reduce inflammation levels by targeting Annexin A5, effectively alleviate the level of pulmonary fibrosis in model mice, and improve their exercise capacity. Compared with the positive drug pirfenidone, the dosage of caffeic acid is only one-tenth of that, which is safer and more effective. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The results of identification of the covalent target of caffeic acid in senescent cells in Example 1 are shown, wherein Figure A: Caffeic acid competes with the IAA probe for binding to the cysteine residue of the protein in senescent A549 cells, the left figure is the in-gel fluorescence result, the right figure is the Coomassie Brilliant Blue (CBB) staining result, and the asterisk indicates the target position for subsequent verification; Figure B: Identification of protein targets in senescent A549 cells by ABPP; Figure C: High concentration of caffeic acid can compete with DBIA for labeling Annexin A5 through the Cys316 residue; Figure D: Pull-down experiment results of the interaction between caffeic acid and Annexin A5 protein in cells.
[0043] Figure 2 The binding mode of caffeic acid to Annexin A5 protein in Example 2 is shown, wherein Figure A: the results of in-gel fluorescence assay of competition between caffeic acid or its oxidized form and IAA probe for protein binding; Figure B: the results of MST experiment; Figure C: the results of CETSA experiment; Figure D: the results of quantitative statistics in Figure C.
[0044] Figure 3 The binding mode of caffeic acid to Annexin A5 protein in Example 2 is shown, wherein Figure A: the results of in-gel fluorescence measurement of wild-type or C316A mutant Annexin A5 protein mediated by caffeic acid probe; Figure B: the results of Western blotting experiment; Figures C to D: the changes in the concentration of TNF-α or IL-1β in the culture medium of non-senescent or senescent A549 cells transfected with interfering siRNA or Annexin A5 siRNA after treatment with DMSO or 25μM caffeic acid.
[0045] Figure 4The results of the effect of the interaction between caffeic acid and Annexin A5 on protein function and downstream signal transduction in senescent cells in Example 3 are shown, wherein Figure A: detection of Annexin A5 protein levels in senescent A549 cells at different time points after treatment with 25 μM caffeic acid; Figure B: effect of BafA1 and MG132 on caffeic acid-induced Annexin A5 protein degradation; Figure C: schematic diagram of conformational changes caused by covalent binding of caffeic acid to Annexin A5 protein; Figure D: ANS fluorescence detection results.
[0046] Figure 5 The therapeutic effect of caffeic acid on the bleomycin-induced mouse pulmonary fibrosis model in Example 4 is shown, wherein Figure A: treadmill experiment results; Figures B to D: concentration results of TNF-α, IL-6 and IL-1β in the serum of model mice; Figure E: Masson staining results; Figure F: expression level of Annexin A5 protein in the lungs of model mice in immunohistochemistry experiments.
[0047] Figure 6 Representative H&E staining results of the lungs of model mice after treatment with caffeic acid or pirfenidone in Example 4 are shown, with a scale bar of 100 μm. DETAILED DESCRIPTION
[0048] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments and drawings. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation to the present invention.
[0049] 1. Reagents and Materials
[0050] Caffeic acid (CA) (purity ≥98%) was purchased from Beijing Better Health Biopharmaceutical Technology Co., Ltd. (Beijing, China);
[0051] Cisplatin (HY-17394), bafilomycin A1 (88899-55-2), and MG132 (133407-82-6) were purchased from MedChem Express, USA;
[0052] 1-anilino-8-naphthalenesulfonate (ANS, A1028) was purchased from SigmaAldrich;
[0053] Click chemistry reaction and LC-MS / MS reagents: TBTA (1770049), TCEP (C4706), Rhodmine-N3 (83689) and CuSO4 (C1297) were purchased from Sigma, USA;
[0054] TMT 10plex TMReagents (A34808), high capacity neutral agarose resin (A53031), and trypsin (90057) were purchased from Thermo Fisher (USA);
[0055] Anti-Annexin A5 (11060-1-AP), phospho-NF-κB (82335-1-RR), anti-NF-κB (80979-1-RR), IL6 (21865-1-AP), p21 (10355-1-AP), p16 (10883-1-AP), and TNF-α (60291-1-Ig) were purchased from Proteintech (Wuhan, China);
[0056] Specific primary antibodies against phospho-PKCθ (sc-271922) and PKCθ (sc-1680) were purchased from Santa Cruz Biotechnology (Shanghai).
[0057] 2. Cell Culture
[0058] A549 and BEAS-2B cells were obtained from the Chinese Academy of Medical Sciences. A549 and BEAS-2B cells were cultured at 37°C and 5% CO2 with DMEM (Corning, USA) supplemented with 10% FBS and 100 IU penicillin-streptomycin. A549 cells were treated with 15 μM cisplatin for 72 hours to induce senescence, and BEAS-2B cells were irradiated with UVA for 20 minutes to induce senescence, and senescent cells were confirmed by SA-β-gal staining.
[0059] 3. Competitive in-gel fluorescent labeling assay
[0060] Senescent A549 cells (1×10 6Cells / well) were placed in a 6 cm culture dish and then treated with different concentrations of caffeic acid (0 μM, 20 μM, 40 μM and 80 μM) for 2 hours. After capturing the cells, 100 μL of RIPA buffer was used for cell lysis. The protein concentration was measured and the cells were then labeled with a cysteine-specific probe (IAA-yne) for 1 hour in a shaker at 37°C. A buffer containing 9 μL TBTA (10 mM in DMSO), 3 μL TCEP (50 mM in deionized water), 3 μL CuSO4 (50 mM in deionized water) and 1 μL TA MRA azide (10 mM in dimethyl sulfoxide) was added to each sample and incubated on a shaker at 37°C for another 2 hours. 1 mL of acetone was added to precipitate the labeled protein, and the precipitated protein was centrifuged at 20,000 g for 10 minutes at -80°C, and the supernatant was discarded. The residual acetone was evaporated, and the samples were dissolved in 100 μL of 1× loading buffer and heat denatured in a metal bath at 90°C for 5 min. The denatured samples were separated by 12% SDS-PAGE gel and the fluorescence was scanned by fluorescence microscopy. The fluorescence was scanned with Azure Sapphire RGB near-infrared scanner. Total protein was visualized by Coomassie Brilliant Blue staining.
[0061] 4. Verify the interaction between small molecules and proteins
[0062] Pull-down experiments were performed to verify the interacting proteins of caffeic acid. As described above, samples were divided into three groups: DMSO, IAA-yne, and CA+IAA-yne. Subsequently, click chemistry reactions were performed in 100 μL of sample with 9 μL 10 mM TBTA, 3 μL 50 mM TCEP, 3 μL 50 mM CuSO4, and 1 μL 5 mM TAMRA-N3 for 2 h. The labeled proteins were precipitated with acetone, dissolved in 1 mL 1.2% SDS / PBS, and heated at 95 °C for 15 min. Diluted to 0.1% SDS with 1× PBS, and then centrifuged at 12000 g for 10 min at room temperature. Then centrifuged at 14000 g for 3 min at room temperature and washed with 1% SDS, 0.1% SDS, and 6 M urea in sequence. Finally, the proteins separated and enriched by SDS-PAGE gel were immunoblotted by adding 1× loading buffer solution and 6 M urea and denatured at 90 °C for 10 min. Immunoblotting was performed using anti-Annexin A5 antibody.
[0063] 5. Proteomic analysis based on cysteine activity
[0064] Competitive mass spectrometry experiments were used to identify potential protein targets of caffeic acid in senescent cells. First, senescent A549 cells were treated with DSMO, 40 μM or 80 μM caffeic acid for 2 hours, and then the cells were lysed and 100 μM DBIA probe (Nanjing Zhuomei Biotechnology Co., Ltd.) was added for labeling in a 37°C shaker. Then, 5 mM DTT and 20 mM IAA were added to alkylate the reduced cysteine residues. DTT and 20 mM IAA were reacted in the dark for 30 minutes. Then 2 μg of trypsin was added to hydrolyze the protein. TMT10plex was then used TM Mass Tag reagent (Thermo Scientific, USA) was used for peptide labeling and enrichment. To enrich peptides, 100 μL Streptavidin beads (Thermo Scientific, USA) were dissolved in 1 ml of PBS in the TMT labeled mixed sample. To eliminate nonspecific binding, the beads were washed three times with 1 mL PBS, 1 mL 0.1% SDS, and 1 mL ddH2O. Finally, desalting was performed with 0.1% formic acid and a commercial C18 column, followed by mass spectrometry analysis.
[0065] 6. Competitive in-gel fluorescence labeling of Annexin A5 protein
[0066] Tyrosine was incubated with caffeic acid to obtain the oxidized form of caffeic acid. In the labeling competition experiment, AnnexinA5 protein was pretreated with caffeic acid, oxidized caffeic acid and IAA for 1 hour. It was then labeled with IAA-alkyne probe. The chemical reaction was then carried out under the above conditions. Finally, the samples were separated in 12% SDS-PAGE gel and subjected to fluorescence scanning. Coomassie Brilliant Blue was used for staining.
[0067] 7. In-gel fluorescent labeling of wild-type and mutant Annexin A5 proteins using caffeic acid probe
[0068] Wild-type and C316A mutant Annexin A5 plasmids were constructed and the recombinant proteins were purified in E. coli. Then, wild-type and mutant Annexin A5 proteins were labeled with caffeic acid probes, followed by click chemistry reactions as described above. Finally, the samples were separated on 12% SDS-PAGE gels and subjected to fluorescence scanning. Total proteins were stained with Coomassie brilliant blue.
[0069] 8. Microscale Thermophoresis (MST)
[0070] The K bond between caffeic acid and AnnexinA5 protein was determined by microscale thermoelectrophoresis (NT.115, Nano Temper Technologies). DValue. The 1mM caffeic acid solution was diluted to different concentrations and mixed with an equal volume of Annexin A5 protein solution (0.2mg / mL) labeled with the Monolith His-Tag Labeling Kit (MO-L018, Nano Temperature Control Technology). These mixtures were then placed in different capillaries and analyzed using MST with a power of 80%. The direct binding of Annexin A5 to caffeic acid was observed by measuring the thermophoretic changes of fluorescent labeled proteins during complex formation. The data were analyzed using MOAffinity analysis software (v2.3).
[0071] 9. Cellular Thermal Shift Assay (CETSA)
[0072] Senescent A549 cell lysates were incubated with DMSO or 50 μM caffeic acid at room temperature for 2 hours and then heated at 37-67°C for 3 minutes. Cells were lysed by centrifugation at 15,000 rpm for 15 minutes at 4°C. The supernatants were then subjected to immunoblot analysis.
[0073] 10. Molecular Docking
[0074] The three-dimensional structure of Annexin A5 protein (PDB ID: 1ANW) was obtained from the RCSB Protein Database (https: / / www.rcsb.org / ). The ANXA5 protein and caffeic acid chemical structures were hydrogenated and dehydrated using Autodock software (version 4.2). Molecular docking was performed using Discovery Studio 2019 client (version 2.5) to determine the optimized binding conformation of the ANXA5-caffeic acid system. The intermolecular interactions were then analyzed using Pymol software (version 2.5), and the intermolecular interaction maps were drawn and analyzed, respectively.
[0075] 11. Western Blot
[0076] Senescent and non-senescent A549 cells were lysed. Proteins were then separated by SDS-PAGE and transferred to PVDF membranes. The PVDF membranes were incubated with primary and secondary antibodies, protein bands were visualized using the Azure C400 system, and analyzed using Image J software.
[0077] 12. Ultraviolet spectroscopy measurement of protein structural changes
[0078] Bis-ANS (b153, Thermo Scientific, USA) was used to analyze the structural changes of wild-type and C311A mutant Annexin A5 proteins before and after caffeic acid treatment. Bis-ANS (b153, Thermo Scientific, USA) is a fluorescent probe that binds to the hydrophobic surface of proteins. 100 μM caffeic acid was added to PBS buffer solution containing 5 μg of wild-type or C316A mutant Annexin A5 protein, and then full-wavelength scanning was performed in the range of 400-700 nm. The scanning conditions were recorded using a microplate reader.
[0079] 13. Pulmonary Fibrosis Mouse Model
[0080] Male BALB / c mice aged 5-8 weeks were purchased from Beijing Life River Experimental Animal Technology Company. Except for the wild-type control group, the remaining mice were instilled with 5 mg / kg bleomycin (BLM) in the trachea to induce pulmonary fibrosis. The BLM-treated BALB / c mice were then randomly divided into three groups. The caffeic acid group, pirfenidone group and model group were gavaged with 10 mg / kg caffeic acid, 100 mg / kg pirfenidone and normal saline every day for 3 consecutive weeks. The body weight of the mice was measured throughout the experiment. Then, three weeks before the test, all mice were euthanized. The visceral organs of mice in each group were collected and fixed in 4% paraformaldehyde for mass spectrometry analysis. Used for Masson staining, HE staining, IHC and determination of inflammatory factors in lung tissue.
[0081] 14. Statistical Analysis
[0082] Statistical analysis was performed using GraphPad Prism 8.0 software (GraphPad Prism, USA). All data are presented as mean ± sem and analyzed using t-test, one-way or two-way ANOVA. Differences were considered statistically significant when P < 0.05, P < 0.01, P < 0.001, or P < 0.0001.
[0083] In the present invention, "non-A549" or "Non-A549" refers to non-senescent A549 cells, and "sen-A549" or "Sen-A549" refers to senescent A549 cells.
[0084] Example 1 Identification of covalent targets of caffeic acid in senescent cells
[0085] In order to further explore the anti-aging mechanism of caffeic acid, this application comprehensively analyzes the direct protein targets of caffeic acid in senescent cells. In terms of chemical structure, caffeic acid has a typical unsaturated ketone group, which can act as a Michael addition receptor to covalently react with the thiol group of cysteine residues in proteins. Therefore, this example uses activity-based competitive proteomics (ABPP) technology to determine potential protein targets.
[0086] First, the ability of caffeic acid to covalently bind to cysteine residues in cell proteins was tested. The results showed that caffeic acid could effectively compete with the fluorescent labeling signal of iodoacetamide (IAA) probe-labeled protein (a cysteine blocker). Figure 1 A).
[0087] This example also performed a proteomic analysis based on cysteine activity, using a desthiobiotin iodoacetamide (DBIA) probe to identify caffeic acid targets across the proteome. Compared with the control group, among the cysteines that reacted with caffeic acid, Cys316 in Annexin A5 was the cysteine that bound most with caffeic acid, with a competition ratio of 36 ( Figure 1 B and Figure 1 C) Annexin A5 is a widely distributed member of the calcium and phospholipid binding protein family, involved in processes such as response, cellular senescence and apoptosis.
[0088] The present application further conducted a pull-down experiment and observed that caffeic acid effectively reduced the enrichment of Annexin A5 protein in samples treated with IAA probe ( Figure 1 D). Taken together, these results suggest that Annexin A5 is a potential target of caffeic acid in senescent cells.
[0089] Example 2 Caffeic acid directly targets Annexin A5 via Cys316
[0090] In this example, recombinant Annexin A5 protein was used to test whether caffeic acid could compete with IAA probe to label the protein in vitro. The results showed that 100 μM caffeic acid completely inhibited the fluorescence signal of 10 μM caffeic acid-labeled Annexin A5 protein ( Figure 2 A). It is worth noting that in order to exclude the possibility that the electron-rich catechol molecules in caffeic acid are oxidized to electrophilic dopaquinone and then covalently bind to the Annexin A5 protein in the cell, oxidized caffeic acid was prepared using tyrosinase. However, compared with caffeic acid, the ability of oxidized caffeic acid to compete with the IAA probe for protein binding is weakened ( Figure 2 A), which indicates that catechol plays an important role in the binding process of Annexin A5 protein.
[0091] This example also uses MST experiment to measure the binding affinity between caffeic acid and Annexin A5 protein in 3.68 μM solution. The results are as follows: Figure 2 As shown in B.
[0092] Cellular thermal shift assay (CETSA) showed that caffeic acid could significantly enhance the thermal stability of Annexin A5 protein, but had no effect on the control protein ( Figure 2 C and Figure 2 D). The direct interaction between caffeic acid and Annexin A5 was further confirmed.
[0093] In order to further verify the binding site of caffeic acid on Annexin A5 protein, the present application synthesized a caffeic acid probe (CA-p), which has similar biological activity as caffeic acid in inhibiting the secretion of SASP by senescent cells. The cysteine residue at position 316 was mutated to alanine, and the mutant protein Annexin A5 (C316A) was purified. The wild-type and point mutant proteins were labeled with the caffeic acid probe. The results showed that the wild-type Annexin A5 protein could be effectively labeled with the caffeic acid-probe, while the labeled fluorescence signal on the mutant Annexin A5 (C316A) protein dropped sharply ( Figure 3 A).
[0094]
[0095] In addition, molecular docking results showed that caffeic acid could form a covalent bond with Cys316 on Annexin A5 protein.
[0096] Finally, the expression of Annexin A5 in A549 cells was knocked down using the corresponding siRNA, and Western blotting was performed to confirm the knockdown efficiency ( Figure 3 B). The results showed that aged A549 cells showed increased secretion of TNFα and IL1β compared with control cells, while knockout of Annexin A5 and caffeic acid could effectively inhibit the secretion of these two inflammatory factors ( Figure 3 C and Figure 3 D). More importantly, in senescent cells with reduced Annexin A5 expression, caffeic acid treatment failed to enhance the inhibitory effect ( Figure 3 C and Figure 3 D), indicating that the function of caffeic acid is mainly dependent on Annexin A5 protein.
[0097] In summary, caffeic acid inhibited the secretion of SASP in senescent cells by directly targeting Annexin A5.
[0098] Example 3 Caffeic acid induces Annexin A5 protein degradation
[0099] This example investigates how the direct interaction between caffeic acid and Annexin A5 affects protein function and downstream signaling in senescent cells.
[0100] First, we tested whether the protein abundance of Annexin A5 was affected by caffeic acid treatment. Western blot results clearly showed that the protein level of Annexin A5 decreased significantly with the increase of caffeic acid treatment concentration and time ( Figure 4 A). Since 25 μM caffeic acid treatment had a significant effect, this concentration was selected in subsequent experiments. Then, bafilomycin A1 (BAF A1) or MG132 was used to inhibit two major protein degradation pathways, the ubiquitin proteasome system (UPS) and the autophagy-lysosome pathway (ALP). The results showed that compared with MG132 treatment, BAF A1 treatment could effectively block caffeic acid-induced Annexin A5 degradation and cause protein accumulation ( Figure 4 B), which means that Annexin A5 is degraded by autophagy. Therefore, the present application speculates that the covalent binding of caffeic acid to Annexin A5 protein leads to conformational changes, such as hydrophobic exposure, which ultimately leads to its degradation ( Figure 4 C).
[0101] To further verify this hypothesis, the present invention uses the fluorescent dye 1-naphthylamine-8-sulfonic acid (ANS), which can bind to the hydrophobic region of Annexin A5 protein, to study the potential effect of caffeic acid on the conformation of Annexin A5 protein. Compared with the control group, the addition of caffeic acid effectively increased the fluorescence signal mediated by ANS ( Figure 4 D), indicating that covalent binding with caffeic acid significantly increased the hydrophobic exposure of Annexin A5. In contrast, for the C316A mutant protein, the fluorescence increase induced by caffeic acid was significantly weakened. These results indicate that caffeic acid, after binding to the C316 residue, leads to the degradation of Annexin A5 protein by inducing hydrophobic exposure.
[0102] Example 4 Caffeic acid alleviates bleomycin-induced pulmonary fibrosis in mice
[0103] This example uses a bleomycin (BLM)-induced pulmonary fibrosis mouse model for animal model experiments. On the second day after the mouse was injected with BLM intratracheally, 10 mg / kg of caffeic acid and the US FDA-approved drug pirfenidone (100 mg / kg, once a day) were gavaged daily for three consecutive weeks as a positive control. A treadmill experiment was used to study the physical function of each group of mice at the end. Compared with the model mice, the present application found that the exercise time of the caffeic acid-treated mice was extended by nearly 10 minutes, which was similar to the positive control group ( Figure 5 A).
[0104] This example also used enzyme-linked immunosorbent assay to detect the levels of various inflammatory factors in mouse serum. The results showed that the concentrations of TNF-α, IL-6 and IL-1β in the caffeic acid treatment group were significantly reduced ( Figure 5 B~ Figure 5 D), consistent with the results of the cell model.
[0105] Next, the applicant dissected the pathological sections of the mouse lungs to verify the mechanism of action of caffeic acid in vivo. The results of hematoxylin and eosin staining showed that in the mice treated with caffeic acid, the lung pathological features such as lung septal thickening were significantly improved ( Figure 6 More importantly, the present application observed that the degree of lung fibrosis in model mice was significantly reduced after caffeic acid treatment, which was consistent with the results of Masson staining ( Figure 5 E) is consistent. Since the present application has confirmed that caffeic acid can induce Annexin A5 protein degradation and inhibit PKCθ activation at the cellular level, the present application further wants to know whether it can also work in mice. Immunohistochemistry data showed that compared with the model group, the expression of Annexin A5 protein in the lungs of mice in the caffeic acid treatment group was significantly reduced ( Figure 5 F). It can be seen that caffeic acid alleviates pulmonary fibrosis by targeting Annexin A5.
[0106] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.
Claims
1. Use of caffeic acid in preparing a drug for regulating or treating a disease associated with AnnexinA5 protein or for degrading AnnexinA5 protein, or use of caffeic acid in preparing an inducer for degradation of AnnexinA5 protein.
2. The use according to claim 1, characterized in that The AnnexinA5 protein-related diseases include aging-related diseases.
3. The use according to claim 1 or 2, characterized in that The diseases associated with AnnexinA5 protein include lung, brain, eye, heart, liver, kidney, blood vessel, bone, skin and / or joint diseases.
4. The use according to claim 1 or 2, characterized in that: The diseases associated with AnnexinA5 protein include lung diseases.
5. The use according to claim 1 or 2, characterized in that: The AnnexinA5 protein-related diseases include at least one of pulmonary fibrosis, pulmonary inflammation, chronic obstructive pulmonary disease, heart failure, myocardial hypertrophy, liver fibrosis, osteoarthritis, intervertebral disc herniation, osteoporosis, Alzheimer's disease, Parkinson's disease, arteriosclerosis, macular degeneration, diabetic nephropathy, diabetic macular edema, and diabetic retinopathy.
6. The use according to claim 1 or 2, characterized in that: The AnnexinA5 protein-related diseases include pulmonary fibrosis and / or pulmonary inflammation.
7. The use according to claim 1 or 2, characterized in that: The AnnexinA5 protein-related diseases include idiopathic pulmonary fibrosis.
8. The use according to claim 1 or 2, characterized in that: The drug or degradation inducer comprises caffeic acid and optional pharmaceutically acceptable excipients.
9. The use according to claim 8, characterized in that: The auxiliary materials include one or more of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, antioxidants, chelating agents, penetration enhancers, pH regulators, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents and filter aids.
10. The use according to claim 1 or 2, characterized in that: The drug or degradation inducer is an injection, tablet, capsule, granule, aerosol, suppository, film, pill, external ointment, controlled release preparation, sustained release preparation or nano preparation.
Citation Information
Patent Citations
Use of compound and composition thereof for preparation of medicine for alleviating inflammation activity of lung cells
CN112007036A
Use of organic acid as method to enhance effect of NRF2 activator
JP2018131429A
Composition and methods for regulating extracellular matrix accumulation
US20190381133A1
Strontium based compositions and formulations for pain, pruritus, and inflammation
WO2016141219A1
